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Sotalol is a beta-adrenergic blocking agent that prolongs
the duration of the cardiac action potential in humans,
without affecting the upstroke velocity of depolarization.
The dextrorotatory isomer, d-sotalol, retains these class
III effects, but has little beta-blocking activity in vitro.
d-Sotalol has not been studied extensively in humans.
The electrocardiographic (ECG) and electrophysiologic
effects of d- and d,l-sotalol were therefore assessed in a
prospective randomized study of 20 patients. Each pa-
tient received either d-sotalol (1, 1.5 or 2 mg/kg body
weight) or d,l-sotalol (1 mg/kg) by intravenous infusion,
The QT and QTc intervals were prolonged and re-
fractoriness increased in the atrium, atrioventricular (AV)
node, His-Purkinje system and right ventricle after both
d.l-Sotalol is a beta-adrenergic blocking agent that prolongs
the duration of the cardiac action potential in vitro, without
affecting the upstroke velocity of depolarization (1-3). These
properties have been designated class III effects (4). Pro-
longation of the monophasic action potential duration has
been demonstrated, both in animals (5) and in humans (6-8).
d.l-Sotalol lengthens the QT interval of the surface electro-
cardiogram (ECG) in humans (7-10) and prolongs atrial
(7-11) and ventricular refractoriness (6,7,9,10-12). It has
antiarrhythmic activity in animals (13,14), and it suppresses
both supraventricular (15-18) and ventricular arrhythmias
(15,16,19-24) in humans.
The dextrorotatory isomer, d-sotalol, has been shown to
be largely devoid of beta-blocking activity in vitro (25-27),
while still prolonging the action potential duration (27,28).
The electrophysiologic properties of d-sotalol in vitro are
similar to those of the racemic mixture, d.l-sotalol, apart
from beta-blockade (27,28). Both d- and d.l-sotalol have
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d- and d,l-sotaloI. After d-sotalol, the increases in both
QT and QTc intervals and in atrial and ventricular ef-
fective refractory periods were dose dependent. Highly
significant linear correlation was demonstrated between
the plasma sotalollevel and the change in QT (r =0.86,
p = 0.001) and QTc intervals (r = 0.79, P = 0.002),
and between the plasma sotalol level and the effective
refractory period of the right atrium (r = 0.75, p =
0,005) and ventricle (r = 0.70, P = 0.025). This study
confirms that d-sotalol has effects consistent with class
III properties. It demonstrates these effects in humans,
and suggests that d-sotalol may prove to be a useful
antiarrhythmic agent.
(J Am Coil CardioI1987;LO:21l-7)
similar antifibrillatory and antiarrhythmic properties in an-
imals (13,29,30). The electrophysiologic properties of d-
sotalol in humans have not yet been described in detail.
This prospective randomized study was performed to assess
the electrophysiologic effects of three doses of d-sotalol in
humans, and to compare them with those of d.l-sotalol.
Methods
Study patients. All patients undergoing routine electro-
physiologic testing because of suspected or documented ar-
rhythmia were considered eligible for this study. Patients
were excluded if they were < 16 or >74 years of age or
had second or third degree atrioventricular (AV) block,
congestive heart failure, chronic pulmonary disease, hy-
pokalemia or a history of intolerance to beta-adrenergic
blocking agents, or if the corrected QT interval (QTc) was
>450 ms. The 20 patients selected for study are described
in Table I. None of the patients had renal disease. The study
protocol was approved by the hospital Human Studies Com-
mittee, and all patients gave written informed consent before
the study.
Protocol. All antiarrhythmic drugs, beta receptor block-
ers and calcium antagonists were withdrawn at least five
half-lives before the study. All studies were performed while
patients were in the fasting state. The first 16 patients were
0735-1097/87/$3.50
212 McCOMB ET AL.
ELECTROPHYSIOLOGY OF d-SOTALOL
JACC Vol. 10, No. I
July 1987:211-7
Table 1. Clinical Characteristics of 20 Patients
d.l-Sotalol d-Sotalol
(n = 8) (n = 12)
Sex 4M,4F IOM,2F
Age (yr)
Range 20 to 74 29 to 69
Mean ± SO 56 ± 20 51 ± 15
Diagnosis
CAD 5 8
MVP 2 I
NSHD I 3
LVEF(%)
Range 25 - 77 26 - 76
Mean ± SO 52 ± 17 55 ± 17
Arrhythmia
VF 0 4
VT I 2
VEA 2 I
SVT 3 I
Syncope 2 2
None 0 2
CAD = coronary artery disease; F = female; LYEF = left ventricular
ejection fraction; M = male; MVP = mitral valve prolapse; NSHD =
no structural heart disease; SYT = supraventricular tachycardia; YEA =
ventricular ectopic activity; YF = ventricular fibrillation; YT = ventricular
tachycardia.
randomly allocated to one of two groups, 8 receiving d.l-
sotalol (l mg/kg body weight) and 8 receiving d-sotalol
(Bristol Myers). The first four patients given d-sotalol re-
ceived I mg/kg, and the remaining four, 1.5 mg/kg. After
completion of the randomized phase of the study, four ad-
ditional patients were given 2 mg/kg d-sotalol. The racemic
mixture, d.l-sotalol, was separated into its isomers by frac-
tional crystallization. The resulting d-sotalol was 98.9%
pure, being contaminated with 1.1% l-sotalol.
Electrophysiologic study. Electrode catheters were in-
troduced percutaneously, through the subclavian and fem-
oral veins, using standard aseptic technique. The catheters
were positioned at the high lateral right atrium, at the tri-
cuspid valve and at the right ventricular apex to record atrial,
His bundle and ventricular electrograms, respectively. All
recordings were made on paper and stored on magnetic tape.
Electrocardiographic intervals, including RR, PR, QRS
and QT, were measured and the QTc interval was calculated.
The QT interval was also measured during atrial pacing at
a cycle length of 600 ms. The AH and HV intervals were
measured during sinus rhythm and during atrial pacing at a
cycle length of 600 ms. Sinoatrial conduction time was
measured using the single extrastimulus technique (31). Si-
nus node recovery time was measured after atrial pacing for
I minute at a cycle length of 600 ms. The sinus node re-
covery time corrected for rest sinus cycle length and the
cycle lengths at which Wenckebach and 2: I AV node block
developed during incremental atrial pacing were recorded.
The effective refractory periods of the right atrium, AV
node and His-Purkinje system were measured by introducing
a single premature atrial extrastimulus (Az) after a drive of
eight beats (AI-AI) at a cycle length of 600 ms. The func-
tional refractory periods of the AV node and His-Purkinje
system were also measured. The effective refractory period
at the right ventricular apex was measured by coupling a
single premature extrastimulus to a drive train of eight beats
at three basic cycle lengths: 600, 500 and 400 ms. The
pacing output was 2.5 mA or five times diastolic threshold,
whichever was greater, and the pulse width was 2 ms in all
patients.
Measurements. As previously determined, d- or d.l-so-
talol was then infused intravenously in 5% dextrose solution
over 10 minutes. The blood pressure was recorded before
the onset of the infusion, and at 2 minute intervals through-
out. The basic ECG and electrophysiologic intervals were
also recorded 2, 5, 7 and 10 minutes after the onset of the
infusion, while the ECG was recorded continuously during
the infusion. Fifteen minutes after completion of the infusion
of sotalol, the ECG and electrophysiologic variables de-
scribed earlier were measured again. Measurements re-
corded in each of the four groups before and after sotalol
infusion were compared using paired t tests.
Sotalol plasma concentrations. Plasma was taken on
completion of the drug infusion (10 minutes after the onset)
and at the time of measurement of the electrophysiologic
variables (30 minutes after the onset of the infusion). The
sotalol concentration in each plasma sample was measured
later using high performance liquid chromatography.
Results
No adverse effects were observed. Systolic blood pres-
sure decreased after administration of d.l-sotalol, from 131
± 20 to 124 ± 24 mm Hg, but this change did not reach
statistical significance, nor was it associated with symptoms
in any patient. There was no change in systolic blood pres-
sure in patients given d-sotalol. Diastolic blood pressure did
not change in either group.
ECG measurements (Table 2). The RR interval in-
creased significantly after the administration of d,l-sotalol
or after the infusion of d-sotalol, 2 mg/kg, but did not change
significantly after d-sotalol, lor 1.5 mg/kg. The QT interval
increased in all groups of patients except in those given I
mg/kg of d-sotalol. Similar changes were observed in the
QTc interval and in the QT interval measured during atrial
pacing. The mean QTc interval increased by 6% in those
given d.l-sotalol and by 2, II and 9%, respectively, in those
given d-sotalol, I, 1.5 and 2 mg/kg. The PR interval in-
creased in all groups of patients, but the increase reached
statistical significance only in those given d.l-sotalol. There
was no significant change in the QRS duration in any group.
Electrophysiologic measurements (Table 3). The AH
JACC Vol. 10, No. I
July 1987:211-7
McCOMB ET AL.
ELECTROPHYSIOLOGY Of d-SOTALOL
Table 2. Electrocardiographic Data in 20 Patients
d.l-Sotalol (n '" 8), d-Sotalo1 (n '" 12)
Interval I mg/kg I mg/kg 1.5 mg/kg 2 mg/kg
RR
preinfusion 725 :±: 74 850 :±: 74 817 :±: 170 710 :±: 160
postinfusion 900 :±: 87 840 :±: 34 885 :±: 168 805 :±: 156
p Value <0.01 NS NS 0.002
PR
preinfusion 195 :±: 44 146 :±: 18 197 :±: 30 155 :±: 31
postinfusion 207 :±: 47 150 :±: 14 207 :±: 41 175 :±: 31
p Value <0.05 NS NS NS
PRap
preinfusion 222 :±: 36 175 :±: 19 245 :±: 49 175 :±: 26
postinfusion 255 :±: 58 187 :±: 31 287 :±: 38 192 :±: 48
p Value 0.045 NS 0.01 I NS
QRS
preinfusion 110 :±: 18 97 :±: 22 92 :±: 10 90 :±: 22
postinfusion 115 :±: 23 99 :±: 28 97 :±: 13 100 :±: 22
p Value NS NS NS NS
QT
preinfusion 369 :±: 17 377 :±: 21 380 :±: 47 362 :±: 30
postinfusion 435 :±: 31 382 :±: 22 440 :±: 53 422 :±: 34
p Value <0.001 NS 0.003 0.003
QTc
preinfusion 435 :±: 26 409 :±: 14 422 :±: 32 433 :±: 17
postinfusion 459 :±: 32 417 :±: 25 468 :±: 17 473 :±: 21
p Value 0.022 NS 0.026 0.026
QTap
preinfusion 361 :±: 31 355 :±: 37 377 :±: 30 360 :±: 32
postinfusion 416 :±: 43 400 :±: 68 430 :±: 42 400 :±: 37
p Value 0.005 NS 0.018 0.006
All measurements are expressed in ms, as the mean:±: I SD before (Pre) and after (Post) infusion of sotalol.
PRap "" PR interval during atrial pacing at 600 ms; QTap "" QT interval during atrial pacing at 600 ms; QTc
'" corrected QT interval.
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interval increased significantly only in those patients given
d,l-sotalol. The HV interval did not change significantly in
any group. The corrected sinus node recovery time also did
not change significantly except in patients given d-sotalol,
2 mg/kg.
The cycle length during atrial pacing at which Wenck-
ebach AV node block occurred increased after both d,l- and
d-sotalol, but this change only reached statistical signifi-
cance after d,l-sotalol and d-sotalol, 2 mg/kg. The cycle
length at which 2: I AV node block occurred also increased
significantly in those given d,l-sotalol.
The right atrial effective refractory period increased in
all groups of patients. The increase was more marked in
those given d.l-sotalol and the higher doses of d-sotalol.
The right ventricular effective refractory period increased
significantly in all groups of patients, at a cycle length of
600 ms. Measured at 500 ms, it increased by 15% (p =
0.001) in those given d.l-sotalol, and by 7% (p > 0.05),
18% (p = 0.011) and 18% (p = 0.037), respectively, in
those given d-sotalol, I, 1.5 and 2 mg/kg.
Determination of the AV node effective refractory period
was limited by atrial refractoriness in nine patients. The
functional refractory period of the node increased signifi-
cantly in those patients given d.l-sotalol and in those given
d-sotalol, 2 mg/kg. The effective refractory period of the
His-Purkinje system could not be measured in most patients,
but the functional refractory period of the His-Purkinje tissue
increased significantly after d.l-sotalol (by 15%), and by 7
and 9%, respectively, after d-sotalol, I and 2 mg/kg.
Plasma sotalol concentrations (Fig. 1-3). There was
a highly significant correlation between the increase in QT
interval and the plasma sotalol concentration in those pa-
tients receiving d-sotalol (r = 0.86, P = 0.001) (Fig. I).
There was also a highly significant correlation between the
change in QTc interval and the sotalol concentration in those
given d-sotalol (r = 0.79, p = 0.002). By contrast, in
patients given d.l-sotalol, despite the presence of significant
prolongation of QT and QTc intervals, the actual magnitude
of the increase correlated poorly with plasma sotalol con-
centration. There was a significant correlation between the
plasma sotalol concentration and the change in both atrial
refractoriness (r = 0.75, P = 0.005) (Fig. 2) and ventricular
refractoriness (r = 0.7, P = 0.025) (Fig. 3) in those patients
who received d-sotalol,
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Table 3. Electrophysiologic Data in 20 Patients
d.l-Sotalol (n = 8), d-Sotalol (n = 12)
Interval I mg/kg I rug/kg 1.5 mg/kg 2 mg/kg
AH
preinfusion 110 ± 24 97 ± 22 110 ± 22 87 ± 10
postinfusion 126 ± 27 100 ± 20 122 ± 30 97 ± 10
p Value 0.014 NS NS NS
AHap
preinfusion 116 ± 27 100 ± 20 122 ± 30 97 ± 10
postinfusion 150 ± 46 115 ± 24 162 ± 56 110 ± 38
p Value 0.042 NS NS NS
HV
preinfusion 52 ± 8 40 ± 0 52 ± 13 45 ± 15
postinfusion 54 ± 9 40 ± 0 55 ± 10 55 ± 13
p Value NS NS NS NS
HVap
preinfusion 58 ± 14 37 ± 5 54 ± II 42 ± 10
postinfusion 57 ± 13 37 ± 5 55 ± 10 45 ± 13
p Value NS NS NS NS
SNRT
preinfusion 1,034 ± 122 1,215 ± 366 1,065 ± 211 985 ± 189
postinfusion 57 ± 13 1,215 ± 256 1,192 ± 273 1,102 ± 242
p Value 0.017 NS NS NS
CSNRT
preinfusion 292 ± 64 337 ± 223 215 ± 121 170 ± 96
postinfusion 266 ± 108 355 ± 205 237 ± 133 220 ± 91
p Value NS NS NS 0.03
SACT
preinfusion 94 ± 39 56 ± 43 100 ± 8 59 ± 9
postinfusion 106 ± 37 80 ± 7 100 ± 30 56 ± 15
p Value NS NS NS NS
AV Wenck
preinfusion 380 ± 49 355 ± 33 432 ± 139 347 ± 46
postinfusion 456 ± 70 380 ± 42 445 ± 159 417 ± 45
p Value <0.001 NS NS 0.044
AV 2:1
preinfusion 321 ± 51 303 ± 45 347 ± 91 303 ± 49
postinfusion 403 ± 61 343 ± 59 370 ± 103 363 ± 31
p Value 0.009 NS NS NS
(continued)
Discussion
Electrocardiographic andelectrophysiologic effectsof
d-sotalol. This study demonstrates that d-sotalol has elec-
trophysiologic properties consistent with class III antiar-
rhythmic effects in humans. The ECG and electrophysio-
logic changes are dose dependent. There is a linear relation
between the plasma sotalol concentration and the increases
both in QT and in QTc intervals and in right atrial and
ventricular refractoriness, after administration of d-sotalol.
At higher doses, the preparation of d-sotalol studied causes
prolongation of sinus cycle length and slowing of AV node
conduction, both of which suggest beta-blockade. This ef-
fect is unlikely to be due to contamination of d-sotalol with
I-sotalol, because the measured concentration of I-sotalol in
the preparation used was only 1.1% and insufficient to cause
the observed effects. Thus d-sotalol, at a dose of 2 mg/kg,
may have intrinsic beta-adrenergic blocking properties. This
study also confirms that d-sotalol has clinical electrophys-
iologic effects similar to those of d.l-sotalol, apart from the
degree of beta-blockade.
Prolongation of the action potential duration by d,l-so-
talol has been demonstrated in vitro (1-3,27,28). Previous
clinical studies (7-11,22) have shown that d,l-sotalollengthens
the QT interval and prolongs refractoriness in the atrium,
AV node (9-1 ),22), His-Purkinje system (10), ventricle
(6,7,9-12,21,22) and accessory pathways (9,12,17). Study
of the electrophysiologic properties of the optical isomers
of sotalol has been less extensive. Both d- and I-sotalol have
similar effects in vitro, apart from beta-blockade (27,28)
and d-sotalol prolongs the QTc interval by 5% and ventric-
ular refractoriness by 11% in the canine heart (29,30). These
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Table 3. Electrophysiologic Data in 20 Patients (continued)
d.I-Soraiol (n = 8), d-Sotalol (n = 12)
Interval I mg/kg I mg/kg 1.5 mg/kg 2 mg/kg
ERP RA
preinfusion 239 ± 25 227 ± 22 230 ± 28 215 ± 17
postinfusion 291 ± 25 250 ± 26 272 ± 22 277 ± 13
p Value <0.001 0.037 0.011 0.01 I
FRP AVN
preinfusion 418 ± 44 397 ± lO 460 :±: 90 392 :±: 43
postinfusion 492 ± 28 402 :±: 24 502 :±: 116 415 :±: 34
p Value 0.006 NS NS 0.018
FRP HPS
preinfusion 420 :±: 33 397 :±: lO 457 :±: 90 402 :±: 41
postinfusion 485 :±: 31 422 ± 21 502 :±: 116 440 ± 40
p Value 0.003 0.030 NS 0.043
ERP RV 600 ms
preinfusion 243 :±: 25 237 :±: 15 240 :±: 16 237 :±: 21
postinfusion 280 :±: 20 253 :±: 15 282 :±: 25 280 ± 36
p Value 0.008 0.038 0021 0.039
ERP RV
preinfusion 240 ± 22 217 :±: 12 225 :±: 13 227 :±: 25
postinfusion 285 :±: 27 230 ± 0 272 :±: 25 260 ± 26
p Value 0.001 NS 0.011 0.037
ERP RV 400 ms
preinfusion 223 ± 21 203 :±: 15 217 :±: 13 212 :±: 21
postinfusion 260 :±: 31 223 ± 6 257 :±: 21 237 :±: 30
p Value 0.001 NS 0.011 NS
All measurements are expressed in ms, as the mean:±: I SD before (Pre) and after (Post) infusion of sotalol.
ap = a measurement during atrial pacing; AV 2: I = cycle length during atrial pacing at which 2: I AV block
occurs; AVN = AV node; AV Wenck = cycle length during atrial pacing at which atrioventricular Wenckebach
block occurs; CSNRT = corrected sinus node recovery time; ERP = effective refractory period; FRP =
functional refractory period; HPS = His-Purkinje system; RA = right atrium; RV = right ventricle; SACT
= sinoatrial conduction time; SNRT = sinus node recovery time.
effects are similar in magnitude to those of I-sotalol (29)
and of d.l-sotalol (13) and suggest that the racemic mixture
and its isomers will have antiarrhythmic activity.
Antiarrhythmic efficacy. Despite this, investigation of
the antiarrhythmic efficacy of d.l-sotalol has been limited.
Figure 1. Relation between the plasma sotalol concentration and
the change in QT interval in patients given varying doses of d-
sotalol: y = 0.013x + 1.025. (e) 1 mg/kg (four patients); (A)
1.5 mg/kg (four patients); (.) 2 mg/kg (four patients).
mcg/ml
25
Figure 2. Relation between the plasma sotalol concentration and
the change in the right atrial effective refractory period (RA ERP)
in patients given varying doses of d-sotalol: y = 0.015x + 0.932.
(e) I mg/kg (four patients); (A) 1.5 mg/kg (four patients); (.) 2
mg/kg (four patients).
mcg/ml
25
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A significant reduction in the incidence of ventricular tachy-
cardia associated with ischemia and reperfusion has been
shown after administration of d,l-sotalol (3). Similarly, the
incidence of electrically induced ventricular tachycardia after
canine myocardial infarction is reduced by 60% (13,14), d-
Sotalol has similar antiarrhythmic efficacy in similar models
(29,30). d,l-Sotalol has been used clinically to treat patients
with atrial and ventricular arrhythmias (9,12,15-24). Sev-
eral detailed clinical studies have demonstrated antiarrhyth-
mic efficacy after intravenous (9,12,17,18,21,22) and oral
(17,21-23) administration of d,l-sotalol in patients with
supraventricular (9,12.17,18) and ventricular arrhythmias
(17,21-23). Investigation of the antiarrhythmic activity of
d-sotalol in vivo has been limited to animals.
Conclusions. Currently available class III antiarrhyth-
mic drugs are effective in some patients with either supra-
ventricular or ventricular arrhythmias. The ECG and elcc-
trophysiologic effects demonstrated in this study suggest
that d-sotalol also has class III effects in humans. The com-
bination of class III activity and relative lack of beta-block-
ade is potentially useful, particularly in those patients with
impaired ventricular function. d-Sotalol therefore may prove
to be useful in the management of such patients, and in-
vestigation of its antiarrhythmic efficacy is warranted.
We thank Bristol Myers for providing both d- and d,l-sotalol and for
performing the plasma sotalol measurements.
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